stockrowNatera, Inc.
NTRA Healthcare Diagnostics & Research
Natera, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.3 billion, up 35.9% from fiscal 2024.
- Revenue
- +34.1%
- EPS
- +34.4%
- Free cash flow
- −85.8%
- Total debt
- −0.06%
Quarter to September 2026, against a year earlier
Follow NTRA
Alert me
Natera, Inc. (NTRA) Return on equity
Natera, Inc.'s return on equity over the twelve months to 30 September 2026 was −10.6%, up 3.8 percentage points from fiscal 2025 (−14.3%). Over the past ten years it has ranged from −1,046.5% (fiscal 2015) to −14.3% (fiscal 2025) — the current reading is the highest in ten years. That is below the Diagnostics & Research industry median of 0.00% and above the Healthcare sector median of −26.3%.
Return on equity, annual
Embed this chart
Annual newest first
| Period | Return on equity | Change (points) |
|---|---|---|
| FY2025 | −14.3% | 5.10 |
| FY2024 | −19.4% | 39.69 |
| FY2023 | −59.1% | 21.51 |
| FY2022 | −80.6% | 2.17 |
| FY2021 | −82.8% | (22.72) |
| FY2020 | −60.1% | 20.24 |
| FY2019 | −80.3% | 364.83 |
| FY2018 | −445.1% | (236.44) |
| FY2017 | −208.7% | (139.80) |
| FY2016 | −68.9% | 977.64 |
Against its own ten years
Return on equity against peers
| Company | Return on equity |
|---|---|
| IDXX IDEXX Laboratories, Inc. compare | 68.9% |
| ILMN Illumina, Inc. compare | 32.4% |
| IQV IQVIA Holdings Inc. compare | 21.3% |
| A Agilent Technologies, Inc. compare | 21.0% |
| DGX Quest Diagnostics Incorporated compare | 14.8% |
| LH Labcorp Holdings Inc. compare | 11.5% |
| WAT Waters Corporation compare | 0.00% |
| NTRA Natera, Inc. | −10.6% |
| MTD Mettler-Toledo International, Inc. compare | −736.4% |
| Diagnostics & Research industry median | 0.00% |
| Healthcare sector median | −26.3% |
| Market median | 0.51% |
What Return on equity is
ROE shows how much profit a company earns for its shareholders on the equity they have in the business.
Annual: Net Income Allotted to Shareholders ÷ Average Common Equity; TTM: Net Income Allotted to Shareholders ÷ Average Common Equity (latest quarter)
More on NTRA
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement